Trial Profile

Selective CD28 Blockade With Lulizumab Compared to CNI Inhibition With Tacrolimus in Renal Transplant Recipients

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lulizumab pegol (Primary) ; Antithymocyte globulin; Methylprednisolone; Mycophenolate mofetil; Prednisone; Tacrolimus
Indications Renal transplant rejection
Focus Therapeutic Use

Most Recent Events

20 Mar 2023 Planned End Date changed from 1 Oct 2024 to 22 Sep 2022.
20 Mar 2023 Planned primary completion date changed from 1 Aug 2023 to 22 Sep 2022.
20 Mar 2023 Planned initiation date changed from 1 Oct 2021 to 10 Jan 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com